bioRxiv · 10.1101/2020.03.07.981829
Structural basis for targeting human cancer antigen STEAP1 with antibodies
Abstract
Six-transmembrane epithelial antigen of the prostate (STEAP1) is an integral membrane protein that is highly upregulated on the cell surface of several human cancers, making it a promising therapeutic target. It shares sequence homology with three enzymes (STEAP2-4) that catalyze the NADPH-dependent reduction of iron(III). However, STEAP1 lacks an intracellular NADPH-binding domain and does not exhibit cellular ferric-reductase activity. Thus, both the molecular function of STEAP1 and its role in cancer progression remain elusive. Here, we present a ~3.0 [A] cryo-electron microscopy structure of trimeric human STEAP1 bound to three Fab-fragments of the clinically employed antibody mAb120.545. STEAP1 adopts a reductase-like conformation and interacts with the Fabs through its extracellular helices. Enzymatic assays in human cells reveal that STEAP1 promotes iron(III) reduction when fused to the intracellular NADPH-binding domain of its family member STEAP4, implicating STEAP1 as a functional ferric reductase in STEAP hetero-trimers. Our work provides a foundation for deciphering the molecular mechanisms of STEAP1 and will be instrumental in the design of new therapeutic strategies to target STEAP1 in cancer.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Oosterheert, W., Gros, P.. 2020-03-07. Structural basis for targeting human cancer antigen STEAP1 with antibodies. https://doi.org/10.1101/2020.03.07.981829
Cite the original work for its findings. Save a collection to share your selection of sources.